Fate Therapeutics
$2.41
24H
Market Cap
Volume
Supply
Price Chart
About Fate Therapeutics - FATE
Fate Therapeutics, Inc. is a biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders through its proprietary induced pluripotent stem cell (iPSC) product platform. Their approach involves using iPSCs to produce immune cells designed to target and destroy cancer cells or modulate the immune system.
What are Fate Therapeutics's core values and mission statement?
Fate Therapeutics, Inc.'s mission is to develop innovative cellular immunotherapies for cancer and immune disorders. Their core values include a commitment to scientific excellence, innovation, collaboration, and improving the lives of patients.
Who founded Fate Therapeutics and when?
Fate Therapeutics, Inc. was founded in 2007 by a trio of stem cell scientists, Dr. Paul Grayson, Dr. Philip Gregory, and Dr. Alexander Meissner.
Who leads Fate Therapeutics?
As of my last update, Dr. Scott Wolchko served as the President and Chief Executive Officer of Fate Therapeutics, Inc.
Where is Fate Therapeutics located, and what is its base country?
Fate Therapeutics, Inc. is headquartered in San Diego, California, and its base country is the United States.
On which exchanges is Fate Therapeutics traded?
Fate Therapeutics, Inc. is traded on the NASDAQ stock exchange under the ticker symbol FATE.
Historical data
Fate Therapeutics (FATE) Price Live Data
The live price of Fate Therapeutics (FATE) is $2.41, with a trading volume of 1,083,255 in the last 24 hours. Wrapstocks updates the FATE price in real-time. Fate Therapeutics is down -5.49% in the last 24 hours. The company has a live market cap of $274,445,984.00 and a supply of 113,878,002 FATE stocks.
Fate Therapeutics (FATE) is traded on NASDAQ Stock Exchange, and currently, the market is closed; trading will be resumed in 5 hours and 58 minutes.
